Tumor-infiltrating B lymphocytes promote melanoma progression and resistance to therapy

September 19, 2017, The Wistar Institute

In a multi-institutional collaborative study, scientists at The Wistar Institute and the Medical University of Vienna, Austria, have identified the role of tumor-infiltrating or tumor-associated B-cells ("TABs") in melanoma progression and resistance to targeted therapy. This study provides a molecular mechanism that governs the cross-talk between TABs and tumor cells as well as a potential new therapeutic strategy for combating tumors resistant to treatment. The study was published online in Nature Communications.

Advanced is very difficult to treat because even after initially successful treatment, tumors eventually become resistant to conventional and targeted therapies. It is well established that the tumor microenvironment, or the complex of stroma-derived cells and immune cells surrounding cancer cells, plays a role in melanoma progression and therapy resistance. These study results describe how TABs, which account for up to one third of all that infiltrate the tumor, can promote tumor heterogeneity and cancer stem cell-like populations that are associated with drug resistance. In immunity against infections, B-cells and their progeny, the plasma cells, produce antibodies that can eliminate the disease. Antibodies can also be produced against but are rarely effective to eradicate the cancer.

"Our results point to an important cancer-promoting function of tumor-infiltrating B-cells and elucidate the molecular 'conversation' between B-cells and melanoma cells, which eventually favors tumor progression and therapy resistance," said lead researcher Meenhard Herlyn, D.V.M., D.Sc., Caspar Wistar Professor and director of The Wistar Institute Melanoma Research Center.

Herlyn, Rajasekharan Somasundaram, Ph.D., Research Assistant Professor in the Molecular and Cellular Oncogenesis Program at Wistar, Stephan N. Wagner, M.D., from the Medical University of Vienna, and colleagues used a co-culture system of melanoma cells and B-cells to evaluate the reciprocal effect of the interaction between these two cell types. By using this approach, they could identify those inflammatory factors produced by B-cells and that were relevant for the interaction and can be used as potential targets for novel therapy. The researchers also analyzed tissue samples from melanoma patients and confirmed the prevalence of TABs in advanced, therapy-resistant tumors tissues. Additionally, these tissues showed increased expression of insulin like growth factor (IGF)-1 and fibroblast growth factor receptor (FGFR)-3, identified as crucial players in the B cell-melanoma cross-talk and potential new therapeutic targets for .

Importantly, the study also included a pilot multicenter clinical trial to evaluate the therapeutic potential of B-cell depletion in therapy-resistant advanced melanoma patients using a monoclonal antibody that specifically binds to CD20, a molecule present on the surface of these cells, thereby causing their death.

"Our results describe a novel mechanism of drug resistance in melanoma induced by tumor-infiltrating B-cells," said Somasundaram, first and one of the corresponding authors of the paper. "This study also provides a clinical basis for developing a novel therapeutic approach for advanced melanoma based on targeting infiltrating B-."

Explore further: Link established between a molecular driver of melanoma and novel therapeutic agent

Related Stories

Link established between a molecular driver of melanoma and novel therapeutic agent

September 7, 2017
Results of a study by The Wistar Institute have described a correlation between a key melanoma signaling pathway and a novel class of drugs being tested in the clinic as adjuvant therapy for advanced melanoma, providing useful ...

Anti-aging gene identified as a promising therapeutic target for older melanoma patients

February 23, 2017
Scientists at The Wistar Institute have shown that an anti-diabetic drug can inhibit the growth of melanoma in older patients by activating an anti-aging gene that in turn inhibits a protein involved in metastatic progression ...

Modulating T-cell metabolism uncovers new technology for enhancing immunotherapy

September 11, 2017
T lymphocytes found in tumors and implicated in killing tumor cells cope with the shortage of oxygen and nutrients in the tumor microenvironment by using fat as the main source of energy. Promoting a switch from glucose to ...

Diabetes drug points the way to overcoming drug resistance in melanoma

June 11, 2013
Advanced metastatic melanoma is a disease that has proven difficult to eradicate. Despite the success of melanoma-targeting drugs, tumors inevitably become drug resistant and return, more aggressive than before. In the current ...

Aging impacts therapeutic response of melanoma cells

April 4, 2016
Cancer risk increases with one's age as accumulated damage to our cells and chronic inflammation occur over time. Now, an international team of scientists led by The Wistar Institute have shown that aged tumor cells in melanoma ...

Researchers discover mechanism leading to BRAF inhibitor resistance in melanoma

June 19, 2015
The development of targeted therapies has significantly improved the survival of melanoma patients over the last decade; however, patients often relapse because many therapies do not kill all of the tumor cells, and the remaining ...

Recommended for you

Student develops microfluidics device to help scientists identify early genetic markers of cancer

October 16, 2018
As anyone who has played "Where's Waldo" knows, searching for a single item in a landscape filled with a mélange of characters and objects can be a challenge. Chrissy O'Keefe, a Ph.D. student in the Department of Biomedical ...

A bad influence—the interplay between tumor cells and immune cells

October 16, 2018
Research at Huntsman Cancer Institute (HCI) at the University of Utah (U of U) yielded new insights into the environment surrounding different types of lung tumors, and described how these complex cell ecosystems may in turn ...

Technique to 'listen' to a patient's brain during tumour surgery

October 16, 2018
Surgeons could soon eavesdrop on a patient's brain activity during surgery to remove their brain tumour, helping improve the accuracy of the operation and reduce the risk of impairing brain function.

Researchers elucidate roles of TP63 and SOX2 in squamous cell cancer progression

October 16, 2018
Squamous cell carcinomas (SCCs) are aggressive malignancies arising from the squamous epithelium of various organs, such as the esophagus, head and neck, lungs, and skin. Previous studies have demonstrated that two master ...

Function of neutrophils during tumor progression unraveled

October 15, 2018
Researchers at The Wistar Institute have characterized the function of neutrophils, a type of white blood cells, during early stages of tumor progression, showing that they migrate from the bone marrow to distant sites and ...

Delving where few others have gone, leukemia researchers open new path

October 15, 2018
A Wilmot Cancer Institute study uncovers how a single gene could be at fault in acute myeloid leukemia (AML), one of the deadliest cancers. The breakthrough gives researchers renewed hope that a gene-targeted therapy could ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.